Outsourced Pharma Webinars

  1. A Systematic Approach To Extractables And Leachables: A Review Of Guidance From The Industry
    12/11/2018

    This presentation discusses the basic definitions of extractables and leachables and why it is important to reference the vast amount of reference material available to ensure that you are meeting industry standards. Understand the role of the supply chain, what departments/positions within your company need to be involved, as well as many other factors to consider such as the machine, drug substance, material, water, and container closure system environment when designing your extractable/leachable study.

  2. Cell-Based Assays In A GMP Environment: Approaches For Clinical And Commercial Stability Studies
    12/11/2018

    This presentation discusses some basics of cell-based assay and why it's the preferred method to support potency analysis for bio therapeutic drugs; developing and optimizing cell-based potency assay; understanding phase appropriate method validation as well as an overview of the typical workflow to transfer cell-based potency assay into a GMP environment and best practices to maintain the long term performance of the assay.

  3. Optimizing Your Plate-Based Assay Workflows
    11/27/2017

    Using workflow based software solutions to guide scientists through various processes in low to high throughput screening campaigns.

  4. Leveraging Machine Learning For Decision Making In The Lab
    11/27/2017

    This webinar explores use cases showing how machine learning and analytics can help overcome the challenges facing the biopharma industry through more confident data-driven decisions.

  5. Looking Under The Hood Of The Unified Lab
    11/22/2017

    Striving to bring the way we acquire, share and gain insights from scientific data, through a community and the framework for standardization and linked data.

  6. Solvents, Polymers & Cyclones: Bioavailability Enhancement Through Spray-Dried Dispersions
    11/2/2017

    Very few new molecular entities in active clinical development are readily bioavailable, and when dosed at escalated levels, even these may not be sufficiently absorbed.

  7. Challenges And Opportunities In The Development Of Biologic Drugs
    7/20/2017

    With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.

  8. Optimize Biologic Drug Development With The Power Of Scientific Informatics
    7/20/2017

    The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.

  9. Visibility and Oversight: What Paper Informed Consent Isn’t Offering You (Featuring Guest Speaker, Chesapeake IRB)
    3/8/2017

    Chesapeake IRB and CRF Health team up for a collaborative webinar to discuss informed consent oversight and visibility and why Top Pharma is turning to Electronic Informed Consent (eConsent) to exceed in these areas.

  10. The World’s Best eCOA Body Map: How Patients Improved Symptom Location Reporting
    3/7/2017

    The burden of ineffective and inefficient body maps creates risks that can impact data quality. We knew we could come up with something much better - for all stakeholders.